Table 3.
Multivariate analysis of PFS and OS
| PFS
|
OS
|
|||
|---|---|---|---|---|
| HR (95% CI) | p-values | HR (95% CI) | p-values | |
| ALRI (≥14 vs <14) | 1.35 (1.02–1.79) | 0.034 | 1.35 (1.01–1.83) | 0.048 |
| Age (continuous variable) | 1.00 (0.98–1.01) | 0.818 | 0.99 (0.98–1.01) | 0.222 |
| Gender (male vs female) | 0.81 (0.62–1.07) | 0.139 | 0.87 (0.65–1.16) | 0.349 |
| ECOG PS (1–2 vs 0) | 1.33 (0.94–1.88) | 0.109 | 2.18 (1.50–3.18) | <0.0001 |
| Tumor localization (colon vs rectum) | 0.98 (0.72–1.34) | 0.908 | 1.09 (0.79–1.51) | 0.585 |
| CT regimen (FOLFIRI vs FOLFOX4) | 1.27 (0.95–1.70) | 0.104 | 1.07 (0.79–1.44) | 0.659 |
| KRAS status (mutated vs wild type) | 0.98 (0.75–1.30) | 0.910 | 1.17 (0.87–1.56) | 0.296 |
| ITACa treatment (CT+B vs CT) | 0.84 (0.64–1.11) | 0.230 | 1.19 (0.89–1.59) | 0.228 |
| LDH (>UNL vs ≤UNL) | 1.20 (0.90–1.60) | 0.202 | 1.30 (0.96–1.76) | 0.095 |
| Liver metastasis | ||||
| Only 1 lesion <5 cm vs no liver mts | 0.55 (0.28–1.06) | 0.076 | 0.62 (0.30–1.27) | 0.191 |
| Multiple liver lesions or 1 liver lesion ≥5 cm vs no liver mts | 1.09 (0.78–1.52) | 0.624 | 1.15 (0.81–1.64) | 0.437 |
Abbreviations: ALRI, aspartate aminotransferase-lymphocyte ratio index; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; ITACa, Italian Trial in Advanced Colorectal Cancer; LDH, lactate dehydrogenase; PFS, progression-free survival; OS, overall survival; UNL, upper normal limit.